EBS Emergent BioSolutions
Price Chart
Executive Summary
Emergent BioSolutions announced a $54 million contract extension with the U.S. government for VIGIV, a treatment for smallpox vaccine complications, and $6.6 million in new international orders for its ACAM2000 smallpox vaccine. These contracts reinforce the company's role in global biodefense preparedness and follow recent agreements with Canada worth up to $140 million CAD.
Key Financial Metrics
Actionable Insight
Traders should monitor near-term revenue recognition from the U.S. and Canadian contracts, particularly the $35M+ CAD expected in 2026. The recurring nature of international orders suggests potential for further demand, supporting valuation upside in a low-market-cap biodefense play.
Key Facts
- Secured $54 million USD U.S. government contract (ASPR) for CNJ-016® (VIGIV) under an existing 10-year agreement
- Received $6.6 million USD in new international orders for ACAM2000® smallpox vaccine from a recurring customer
- Recent multi-year agreements with Government of Canada valued up to $140 million CAD, with over $35 million CAD expected in 2026
- Contracts support national and global biodefense strategies amid rising biological threat concerns
Financial Impact
$60.6 million in new or incremental contract awards (including $54M U.S. and $6.6M international); over $35M CAD (~$25.5M USD) expected revenue in 2026 from Canada
Risk Factors
- Revenue recognition timing may be back-end loaded or dependent on delivery milestones
- Forward-looking statements subject to execution risk and government procurement delays
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262595 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
20d ago
|
Press Release
| $8.47 $9.13 | ▲ +7.79% | ▲ +5.45% | $8.23 (−2.83%) |
|
Apr 30, 2026
21d ago
|
Insider Cluster
| $8.23 $9.10 | ▲ +10.57% | ▲ +8.84% | $8.23 (−0.00%) |
|
Apr 29, 2026
22d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
Apr 29, 2026
22d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
Apr 28, 2026
22d ago
|
DEFA14A
| $8.23 $8.54 | ▲ +3.77% | ▲ +2.07% | $8.23 (−0.00%) |
|
Apr 28, 2026
23d ago
|
Press Release
| $8.23 $8.54 | ▲ +3.77% | ▲ +2.07% | $8.23 (−0.00%) |
|
Apr 27, 2026
23d ago
|
DEFA14A
| $8.23 $8.54 | ▲ +3.77% | ▲ +2.07% | $8.23 (−0.00%) |
|
Apr 16, 2026
4w ago
|
Press Release
| $8.81 $8.03 | ▼ −8.85% | ▼ −9.41% | $8.23 (−6.58%) |
|
Apr 16, 2026
4w ago
|
Press Release
| $8.81 $8.03 | ▲ +8.85% | ▲ +9.41% | $8.23 (+6.58%) |
|
Apr 16, 2026
5w ago
|
DEFA14A
| $8.62 $8.09 | ▼ −6.15% | ▼ −7.13% | $8.23 (−4.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access